Publication Topic

Wu E, Jensen IS, Cyr PL, Kisner H. Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs. American Society of Hematology, Atlanta GA, 2017.

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.

Sacks NC, Liu Y, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J… Cyr PL, et al. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. American Heart Association Scientific Sessions, Anaheim CA, 2017.

Jensen IS, Wu E, Sacks N, Cyr P, Chung K. 2017. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Blood 130(Sup 1):5615; 10.1182/blood.V130.Suppl_1.5615.5615.

Young LY, Sacks NC, Cyr PL, Sharma A, Dahdal DN. 2017. Comparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy. Sage Open Med 5(Aug 31):2050312117727999; doi: 10.1177/205031211772799.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.